Amgen and Bushu Pharma Announce Expanded Supply Chain Partnership across Japan and Asia-Pacific Region

Bushu Pharmaceuticals Ltd., has agreed on an expanded partnership with Amgen Inc. and Amgen K.K. to provide its "Gateway to Asia" service to four countries across the Asia-Pacific region as Amgen's contract manufacturing organization (CMO). An integral factor in Amgen's business growth in Japan, Bushu Pharma has partnered with Amgen since 2016 to assure pharmaceutical drug product supply continuity and quality excellence for Amgen patients in Japan. Further reinforcing the value of this partnership, Amgen has awarded Bushu Pharma the expanded Gateway to Asia contract for supply to Amgen's biggest markets, including mainland China, Taiwan and South Korea. The decision is expected to double the current volume of Amgen products being manufactured and packaged by Bushu Pharma -- including Repatha, Evenity, Prolia, and Xgeva. The scope of the work under Bushu Pharma's Gateway to Asia services will be to assemble, label, package and inspect the products for those markets, with the first supply of these drugs set to commence this year. For the joint press release with Amgen, please refer: https://www.bushu-pharma.com/en/amgen-and-bushu-pharma-announcement/ Tadao Takano, Chief Operational Officer and President at Bushu Pharma, said, "We are pleased to have built a strong partnership through successful launches of Amgen's four (Repatha, Evenity, Blincyto, and Aimovig) innovative drugs in Japan and scaled production to match the growing patient needs. The new Gateway to Asia services will enable further effectiveness in importing bulk products to Japan for quality inspection, labeling, packaging and distribution throughout Japan and Asia-Pacific." In addition to this agreement with Amgen, Bushu Pharma has also recently established its Kazo Packaging Center and agreed on a business alliance with Suzuken Co., Ltd. through which the company will provide comprehensive support for new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market. Bushu Pharma's Gateway to Asia service offers global manufacturers like Amgen the chance to efficiently enter and grow their sales in Japan and across the Asia-Pacific region.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!